Recurrent or Metastatic NSCLC

An open label two-stage phase II, study of orally administered BKM 120 in patients with recurrent or metastatic non-small cell lung cancer with activated PI3K pathway.

NSCLC

A phase II single-arm trial of BIBW 2992 (Tovok™) in demographically and genotypically selected non-small cell lung cancer patients.

• Study Phase II
• Selection criteria

NSCLC, stadium III

Concurrent helical tomotherapy with chemotherapy in unresectable stage III non-small cell lung cancer (NSCLC): a phase I/II trial of radiation dose escalation and fixed dose chemotherapy.

• Study Phase I/II
• Selection criteria

SCLC

A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of First-Line Chemotherapy.

• Study Phase III
• Selection criteria

NSCLC, stage IIIB/IV or recurrent

A Multicenter, randomised, double-blind, phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard docetaxel therapy compared to placebo plus standard docetaxel therapy in patients with stage IIIB/IV or recurrent non small cell lung cancer after failure of first line chemotherapy.

• Study Phase III
• Selection criteria

Advanced disease

A randomized discontinuation study of Brivanib alaninate (BMS-582664) versus Placebo in Subjets with advanced tumors.

• Study Phase II
• Selection criteria

NSCLC,stage III

A Prospective multicenter randomised phase III study to evaluate the efficacy of Zometa (zoledronic acid) in the prevention or delaying of bone metastasis in patients with stage III non-small cell lung cancer (NSCLC).

• Study Phase III
• Selection criteria

NSCLC, EGFR mutatie

FIELT: Prospective ealuation of small molecule EGFR-1 tyrosine kinase inhibition as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) harbouring a mutant EGFR gene.

• Study Phase II
• Selection criteria

NSCLC, resected stage IB-II

Toledo: Randomized Phase II study Evaluating the tolerability of adjuvant Deocetaxel-based chemotherapy for completely resected Stage IB-II Non-Small Cell lung Cancer. TOGA

• Study Phase II
• Selection criteria

NSCLC, stage IIIb / IV

A Phase III randomized, double-blind, placebo-controlled multi-center study of ASA404 in combination with paclitaxel and carboplatin as first-line treatment for locally advanced or metastatic (stage IIIb/IV) non-small cell lung cancer (NSCLC).

• Study Phase III
• Selection criteria

NSCLC

A double-blind, randomized, placebo-controlled phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-specific cancer immuno therapeutic as adjuvant therapy in patients with resectable MAGE-A3 positive Non Small Cell Lung Cancer.

• Study Phase III
• Selection criteria

Adenocarcinoom

• Study Phase III